Preliminary results from a phase II trial indicate that ivonescimab combined with chemotherapy may be an effective first-line treatment for advanced thymic carcinoma. The study also includes biomarker analyses that could inform future treatment strategies.
ivonescimab plus chemotherapy as first line treatment for advanced thymic carcinoma preliminary results of a phase ii trial with biomarker analyses
Original title: “Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.”